| Can-Fite BioPharma (NYSE American: CANF) Explores the anti-Coronavirus Effects of Piclidenoson |
| |
|
Can-Fite BioPharma (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, entered a collaborative research agreement with the Lewis Katz School of Medicine at Temple University to explore anti-viral activity of Piclidenoson on Coronaviruses viral load in a mammalian cell model system as a first step to developing a treatment.
Why It Matters: In some patients, coronaviruses create uncontrolled immune response and rheumatoid arthritis drugs may be used for treatment. Recently, China has approved the use of Roche’s Actemra, approved by U.S. FDA to treat rheumatoid arthritis, to treat coronavirus patients with serious lung damage. Moreover, Gilead is conducting a clinical study in China combining its rheumatoid arthritis drug chloroquine with its anti-viral candidate in the treatment of coronavirus.
Key Quote: “We are privileged to work with Dr. Khalili, a Key Opinion Leader in the arena of neurosciences and virology, to further study and advance our understanding of the effect of Piclidenoson on the coronaviruses replication and molecular mechanism involved. This work aims to provide a more solid foundation for our ongoing efforts to understand the potential of Piclidenoson in these therapeutic areas.” – Dr. Pnina Fishman, CEO
The Backstory: Can Fite’s drug Piclidenoson is currently in Phase III study for the treatment of patients with rheumatoid arthritis and on top of it has been shown to possess anti-viral effects against 2 single stranded RNA viruses HIV and HCC. The Coronaviruses are also single stranded RNA viruses. Can-Fites’s Piclidenoson’s anti-viral effect is protected by U.S. patent US7589075.
Disclosure
Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a cash fee of $5,000 monthly, beginning in August 2019, and 16,500 shares of CANF Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| CytoDyn (OTCQB: CYDY) Files Modified IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus |
| |
|
CytoDyn (OTCQB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced the Company filed a modified IND and protocol for its Phase 2 clinical trial with leronlimab (PRO 140) as a therapy for patients who experience respiratory complications as a result of contracting Coronavirus Disease 2019 (COVID-19). The modification came at the behest of the U.S. Food and Drug Administration (FDA) in response to the Company’s filing of its IND and protocol for its Phase 2 clinical trial on March 9, 2020.
Why It Matters: The modified protocol is a Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients with Coronavirus Disease 2019 (COVID-19) and calls for 75 planned patients in up to 10 centers in the United States. Patients enrolled in the trial are expected to have a treatment window of approximately 6 weeks.
Key Quote: “We are pleased with the new trial design and are rapidly sending supplies of leronlimab to the clinics to begin patient treatment.” – Nader Pourhassan, Ph.D., President & CEO
The Backstory: CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients and plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer.
Disclosure
CytoDyn (CYDY) is a client of RedChip Companies, Inc. CYDY agreed to pay RedChip Companies, Inc., a $20,000 quarterly cash fee, beginning in February 2020, for RedChip investor awareness services.
|
|
| |
|
| Nemaura (NASDAQ: NMRD) Enters Into Multiple Verbal Non-Binding Agreements for its sugarBEAT® Platform |
| |
|
Nemaura Medical (NASDAQ: NMRD) entered into multiple verbal non-binding agreements for sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), with the aim of securing regional and global partnerships.
Why It Matters: The verbal non-binding agreements are expected to lead to discussions for licensing and collaboration on a regional or global scale, following the appropriate mutual due diligence processes. However, there can be no assurance that the foregoing will occur as planned, or at all.
Key Quote: “Collaborating with highly capable strategic partners as we seek to bring the first ever non-invasive continuous glucose monitoring system to market, is a key initiative for management. Given the importance of this initiative we thought it appropriate to share this update on the progress over the course of the last few months that has been made with potential partners for large scale collaborations that we believe will help us accelerate our speed to market by leveraging off the resources and established networks of multinational companies in this field.” – Dr. Faz Chowdhury, CEO
The Backstory: The first phase of the commercial launch of sugarBEAT® began in the UK after the Company received CE Mark approval in 2019. In this initial phase, devices were supplied to a limited cohort of users while the Company focused on scaling up its manufacturing operations. The UK licensee of sugarBEAT®, DB Ethitronix, is currently in the process finalizing the launch of online sales of sugarBEAT®. The Company is currently planning a user study comparing sugarBEAT® directly against a highly successful major incumbent CGM sensor with the goal of positioning sugarBEAT® as a non-invasive, daily/flexible, cost-effective alternative to traditional, expensive and invasive CGM. The global total addressable market for CGM is estimated at $82 billion per annum, consisting of $12.7 billion for Type 1 insulin users (5% of diabetes), $38.0 billion for Type 2 insulin users (15% of diabetes) and $31.4 billion for Type 2 non-insulin users (80% of diabetes). These numbers exclude the prediabetes population which is estimated at nearly three times as large as the diabetes population.
Disclosure
Nemaura Medical (NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee of $6,000 and 15,000 shares of Rule 144 stock for three months of investor awareness services.
|
|
| |
|
| SinglePoint (OTCQB: SING) Launches Klen Hands - Hemp Seed Oil Infused Hand Sanitizer |
| |
|
SinglePoint (OTCQB: SING) debuts new hand sanitizer product and launches website for preorders. Shipments are expected to begin shipping in approximately 10 business days.
Why It Matters: Hand sanitizer is one of the most out of stock products there is in most all retail locations. The Company expects to sell out very quickly as concerns over coronavirus continue. SinglePoint’s hand sanitizer has 62% ethyl alcohol to keep hands klen (clean) as well as hemp seed oil to keep hands soft and hydrated. Klen is currently being produced in SinglePoint's Carlsbad facility and will ship directly to customers.
Key Quote: “It is beneficial that we have a manufacturing facility already making other CBD/Hemp products and the relationships to quickly get supplies. This product is the right time and the right place. We are very happy with how quickly we were able to put it all together and believe this product will be on retail shelves year-round as a permanently stocked item.” – Greg Lambrecht, CEO
The Backstory: Founded in 2011 SinglePoint, Inc (SING) invests in and acquires brands and companies that will benefit from injection of growth capital and the sales and marketing expertise of SinglePoint. The company portfolio currently includes solar, hemp and technology applications. SinglePoint is working to grow the company to a multinational brand.
Disclosure
SinglePoint, Inc. (SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2019, for RedChip investor awareness services and consulting services.
|
|
| |
|
| SPI Energy (NASDAQ: SPI) Announces Sale of Sun Roof I Solar Project in Italy |
| |
|
SPI Energy (NASDAQ: SPI), a global provider of green energy solutions for business, residential, government, utility customers, and investors, today announced the closing of the sale of its Sun Roof I assets, a 479 kWp rooftop solar project located in Aprilia, Italy, that has been in operation since 2012.
Why It Matters: Proceeds from the sale were approximately EUR 1.1 million before transaction fees, strengthening the Company’s balance sheet and providing additional capital for the development of solar assets in the US.
Key Quote: “We are excited about the successful sale of Sun Roof I, which followed the sale of Sun Roof II and Sun Roof V to the same buyer. The sale is part of our strategic plan to consolidate our solar platform in Europe as we continue to grow our solar projects pipeline in the United States, such as the recently announced acquisition of the Oregon Portfolio.” - Xiaofeng Peng, CEO
The Backstory: SPI is a global provider of photovoltaic (“PV”) solutions for business, residential, government and utility customers and investors. The Company develops solar PV projects that are either sold to third party operators or owned and operated by the Company for selling of electricity to the grid in multiple countries in Asia, North America and Europe. The Company’s subsidiary in Australia primarily sells solar PV components to retail customers and solar project developers. The Company has its operating headquarter in Hong Kong and its U.S. office in Santa Clara, California. The Company maintains global operations in Asia, Europe, North America and Australia.
Disclosure
SPI Energy (SPI) is a client of RedChip Companies, Inc. SPI agreed to pay RedChip Companies, Inc. 25,000 shares of Rule 144 stock and a monthly cash fee of $6,500, beginning in August 2019, for 12 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| |
| Quote of the Week |
| |
"There can be tremendous rewards in this space, but you must be careful."
- Greg Sichenzia, Sichenzia Ross Friedman Ference LLP |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2020 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
